Oncotarget Steps Up Campaign against Cancer through Weekly Publications

The ultimate goal of cancer studies is to fight and eliminate the dreading condition. This is what Oncotarget, an online medical research publication firm insists in their journals. An article titled “Nature Review Cancer from Oncotarget published on SCImago” addresses the importance of conducting diagnosis research on the oncology subject. To diagnose lesions that are precancerous, the article suggests the importance of understanding the main trigger of the cancer condition. This publication edited by Oncotarget shows how effective the journal is in promoting scientific research necessary to kick cancer out of the world.Another article from Oncotarget by Business Wire highlights the recent announcement by IntraGen about a publication deal they procured with Oncotarget. IntraGen, an oncology research company, announced that the results obtained from the study they did on tumor samples obtained from patients titled New EPOC were published by Oncotarget. Overall, this is a plus from Oncotarget as the move is seen to boost their publication portfolio. This step is also very vital in their research program campaign against cancer. The new EPOC results provide clinicians extra insights needed to develop cancer treatment solutions. With such results, Oncotarget is proud of making important strides each week in the fight against cancer. They are open to ideas and research contributions around the work, provided that the work addresses cancer.

About Oncotarget

Oncotarget is a weekly medical journal founded in 2010. They edit oncology research work globally and they forward the work to Impact Journals for publication. The firm is responsible for editing quality research work that provides cancer solution. The editing team is headed by Mikhail Blagosklonny and the team is effective in delivering verifiable cancer research solutions. The Publication is supplied with informed medical experts who are effective in delivering quality research. Recently, Oncotarget began releasing two articles a week. This is to meet the increasing demand for cancer treatment options. The move is seen as a future approach in the cancer campaign.

Conclusion

Oncotarget through impact Journal is effective in delivering cancer research work. They are able to welcome and edit research work addressing different medical fields such as Pathology, Microbiology, Immunology, and Aging conditions.

The Remarkable Career of Mikhail Blagosklonny

When it comes to research regarding cancer and its therapies, there are individuals who must be given credit due to their impacts in finding solutions to this menace. Mikhail Blagosklonny is one of such names; he is a professor of Oncology at the Rosewell Park Cancer Institute in Buffalo, New York. Mikhail has conducted numerous research projects in cancer and its therapy. He is popular in his advocacy on the use of Rapamycin, a cancer drug whose role is to lengthen the lifespan of the cancer patient. His contribution in this particular field of research is extensive and unparalleled.The work of Mikhail Blagosklonny is driven by his passion to ensure that individuals across the globe can access the best treatment possible irrespective of their financial muscles. Medical research is his area of focus and narrowed specifically on the study of aging as well as cancer. He is specifically interested in finding out the connection between age and cancer. Blagosklonny is interested in understanding why cancer is common in patients above a certain age. He continues to advance research that has and will continue to be of great value in the oncology field.

Mikhail Blagosklonny continues to be a very influential individual. Apart from being a valuable researcher, he is a professor with expertise in his field of specialization. He continues to be a source of inspiration to not only his students but also his peers who want to expand their careers. Mikhail’s interesting topic of cancer, as well as aging, has attracted great attention from experts in the medical field. He has a goal of not only developing a treatment for cancer but also treating the disease effectively and affordably, not the expensive treatment that is there today. Mikhail Blagosklonny seeks to find ways in which the cancerous cells in the body can be eliminated without having adverse effects on the normal cells. Cells are crucial in the recovery of the body and mind of a patient after months or years of treatment. He has made critical progress in this field, and his findings will inspire other researchers across the globe to pick up from where he will leave his research. He believes that effective treatment of cancer in the future will not only be achievable for the rich peoples; it would be a cost-effective treatment for everybody.

Rapamycin is a drug that Mikhail Blagosklonny continues to promote in the treatment of cancer as well as prolonging the lifespan of a human being. Increasing the longevity of human beings is his current research area. He has carried out tests on mice and has proved that employment of Rapamycin on aging mice has enhanced the immunity of these animals on diseases such as tuberculosis. Moreover, tests on human beings have also proven immunological innovation among the elderly when injected with the dose of Rapamycin before being immunized against influenza. Mikhail Blagosklonny continues to provide hope to the long search for effective cancer treatment. His efforts have continued to give people hope against the menace of cancer.

Business Entrepreneur Eric Lefkofsky Joins the Battle Against Cancer:

He has worked in the fields of logistics, technology, and venture capitalism. Now Eric Lefkofsky has jumped into the medical field with his new company Tempus. While he may not have a medical degree, the work he does for doctors could prove invaluable in the battle against cancer.

Lefkofsky’s role in cancer treatment involves something he’s had a great deal of experience in, data collection, and using said data in the best ways possible. What Tempus does is more than the collection of personal patient information. He wants to gather data at the molecular level, combining areas like genomic information and therapeutic data to aid in cancer treatment.

The inspiration for this is personal for Lefkofsky. Years ago, his wife Elizabeth was diagnosed with cancer. During meetings with oncologists, Lefkofsky said he was surprised by how much data they lacked when it came to treatments. This was mainly in the form of lack of information on why groups of people responded to certain types of treatment and others didn’t.

Because of that, Lefkofsky co-founded Tempus in 2016. The technology created by the company would allow doctors to collect a variety of data to determine how best to treat patient. Some of that data would be if the cancer patient also has diabetes or had a drug addiction problem, and how that could affect cancer treatments.

Eric Lefkofsky is a native of Detroit, Michigan who received a law degree from the University of Michigan. His start in the business world was a far cry from the technology-based company Tempus. He sold carpet to earn money while at the University of Michigan. Later, with a family loan, he started an apparel company in Madison, Wisconsin.

Lefkofsky is responsible for founding or co-founding numerous companies. He started InnerWorkings, a procurement service company, Echo Global Logistics, and the e-commerce company Groupon. Outside of his business interests, Lefkofsky serves on the board of directors of Chicago’s Children’s Memorial Hospital and the Art Institute of Chicago.

To know more visit @: www.bizjournals.com/chicago/news/2016/10/04/groupons-eric-lefkofsky-returns-to-the-forbes-400.html